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The importance of the device in asthma therapy 
L. Borgstr6m 
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Abstract Inhalation is the preferred route for drug delivery in asthma treatment. Successful management of asthma 
depends on achieving adequate delivery of inhaled drug to the lungs, and to this end the role of the device used for deliv- 
ery is very important. Aerosolized anti-asthma medications have been available for more than 40 years as pressurized 
metered dose inhalers (pMDIs), but more recently dry powder inhalers (DPIs) have been developed as an alternative. 
Laboratory assessment offi ne particle dose has been shown to correlate to pulmonary deposition if the assessments are 
performed with an in vivo-lil<e set up. The DPI Turbuhaler '~ delivers a high proportion of the dose as fine particles sug- 
gesting high pulmonary deposition.This finding has been confirmed by lung deposition studies, which indicate superior 
pulmonary deposition fromTurbuhaler compared with a p MDI. This superior delivery to the lungs withTurbuhaler is re- 
flected in a better clinical effect, as measured by greater improvements in lung function.The DPIs such asTurbuhaler are 
easy to use, and Turbuhaler has been shown to function well in a constrained situation such as an acute asthmatic exacer- 
bation. Furthermore, the use of Turbuhaler in acute asthma will provide rapid clinical improvement.The in vivo variability 
in lung deposition obtained withTurbuhaler is lower than with pMDI, indicating thatthe performance of Turbuhaler is less 
dependent on patient competence. Thus, the development of Turbuhaler represents an important step forward in the 
effective management of asthma. 
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INTRODUCTION 
Asthma is a disease for which inhaled treatment is gener- 
ally preferred to systemic or oral treatment. Successful 
management of asthma depends on achieving adequate 
delivery of inhaled drug to the lungs, and the role of the 
inhalation device is of major importance. Aerosolized 
asthma medications have been available for more than 
40 years as pressurized metered dose inhalers (pMDIs), 
but there is increasing evidence to show that a large pro- 
portion of asthmatic patients do not benefit fully from 
their drugs because of poor inhaler technique (I). More- 
over, the propellants used to generate the aerosol are of- 
ten chlorofluorocarbons, which are thought to deplete 
the ozone layer and are to be phased out of production 
(2). Consequently, pharmaceutical companies have fo- 
cused their attentions on the development of alternative 
inhaler systems. In this context, dry powder inhalers 
(DPIs) have been proposed as a valuable alternative (2). 
This paper discusses the effectiveness of inhalers, in 
particular the DPI Turbuhaler ~-~', with regard to lung de- 
position and elicited effects.The value of in vitro methods 
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for predicting lung deposition, as well as variability in in- 
haler performance, will also be discussed. 
THE VALUE OF IN VITRO STUDIES FOR 
PREDICTING CLINICAL OUTCOMES 
Pulmonary deposition of inhaled drugs is influenced by 
the size distribution of the inhaled particles. Fine parti- 
cles, defined as those of less than 5/~m in aerodynamic 
diameter, are more likely to reach the lower airways than 
larger particles. Characterization of aerosol formulations 
in the laboratory is important in guiding pharmaceutical 
product development and is used in final quality control. 
If the analytical set-up is modified, in vitro analysis can be 
used to predict lung deposition of the inhaled formulation. 
Traditionally, the cascade impactor has been used to 
classify the particle size distribution of an aerosol in v/tro. 
If the common glass bulb impactor inlet is exchanged for 
an anatomically correct cast of a human throat, the re- 
sults show a good correlation with lung deposition data. 
Measurements of lung deposition can be made in vivo 
using, for example, the charcoal-block method (3). 
Using the described in vitro and in vivo methods, the in 
vitro fine particle dose and the in vivo lung deposition of 
salbutamol was compared for three DPIs (Turbuhaler, 
Rotahaler ~ and Cyclohale¢ ~) and a pMDI (4). Both in 
vitro methods numerically overestimated the amount of 
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lung deposition, although the anatomical throat replica 
resulted in a better  correlation with the observed level 
of lung deposition in humans. More importantly, using 
the adult throat replica as the impactor inlet allows bet- 
ter  comparison of the pMDI data with the DPI results 
than using the glass bulb. This suggests that in humans, 
interaction of the throat with an aerosol cloud from a 
pMDI is stronger than with an aerosol cloud from a DPI. 
An aerosol cloud from a DPI is a stable aerosol while that 
from a pMDI is dynamic and changing. A plot of lung de- 
position against fine particle dose, obtained using the 
anatomical throat replica, shows good correlation (Fig. 
I).This suggests that the use of an anatomically accurate 
throat as the inlet to the cascade impactor may be a step 
forward in the attempt o bridge the in vitro model data 
with lung deposition. 
LUNG DEPOSIT ION AND CLINICAL 
EFFECT 
The development of new inhalation devices has high- 
lighted the issue of the relationship between pulmonary 
deposition and therapeutic effect of inhaled drugs in pa- 
tients with obstructive lung disease. The importance of 
pulmonary deposition for therapeutic effect has been ex- 
amined in a study comparing administration of the 
flz-agonist terbutaline via Turbuhaler and pMDI (5). 
Pulmonary deposition with Turbuhaler was about 20%, 
double that achieved with the pMDI (Fig. 2). This in- 
creased deposition with Turbuhaler was reflected in a 
superior clinical effect, as measured by greater improve- 
ments in forced expiratory volume in I second (FEVI), 
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F igure  I. Correlation between lung deposition ofsalbutamol 
and the fine particle dose obtained using the anatomical throat 
replica as inletto the cascade impactor (4).Two points are shown 
for each DPI, representing moderate and weak inhalation ef- 
forts. TH: Turbuhaler; RH: Rotahaler; CH: Cyclohaler; pMDl: 
pressurized metered dose inhaler. Mean _+SEN. [Reproduced 
with permission from Interpharm Press IncJ 
forced vital capacity (FVC), forced expiratory flow (FEF) 
at 25%, 50% and 75% of FVC (FEFzs, FEFs0, FEF7s, respec- 
tively) and peak expiratory flow rate. This suggests that 
Turbuhaler is the preferred device for inhalation of asth- 
ma drugs when compared with a pMDI. 
A recent study has compared fine particle dose and 
lung deposition of formoterol delivered byTurbuhaler or 
Aerolizer <A> in healthy subjects (6). Both devices showed 
a good correlation between fine particle dose and 
lung deposition. However, lung deposition was 
consistently higher with Turbuhaler compared with 
Aerolizer; on average, 41% more formoterol was depos- 
ited in the lungs withTurbuhaler. 
A clinical study compared the bronchodilatory effect 
of formoterol at doses of 9 #g administered viaTurbuha- 
ler or 12/~g administered via Aerolizer (7). While 
there was a trend for greater therapeutic effect when 
the drug was administered via Turbuhaler, the differ- 
ences were not significant. Possible explanations for the 
absence of significance could be that too few patients 
were included in the study (n= 19), or that the doses used 
were at the upper end of the dose-response curve. Com- 
parisons should ideally be performed using more than 
one dose from at least one of the devices being com- 
pared; this makes it possible to verify that the doses used 
were on the steep part of the response curve. 
The relationship between the site of deposition of a 
drug in the lung and clinical effect is poorly understood. 
More is known about where inhaled drugs are actually de- 
posited than where they should ideally be deposited. It is 
virtually impossible to achieve peripheral deposition 
without some deposition in central areas. While the pro- 
portion of peripheral to central deposition can be 
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Figure 2. Lung deposition after inhalation of 0-25 and 0"5 mg 
ofterbutaline sulphate ither via pressurized metered dose inha- 
ler (pMDI) or via Turbuhaler (TH). Pulmonary deposition 
(mean 4-SD) is expressed as a percentage of the nominal dose 
(5), [Reproduced with permission from Am j Respir Crit Core 
Med.] 
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determined for different inhalation systems, there is little 
evidence to indicate which is more beneficial in terms of 
clinical effect. 
TURBUHALER IN ACUTE ASTHMA 
The efficacy of drug delivery withTurbuhaler is an impor- 
tant issue for the as-needed use of Oxis~'~Turbuhaler '~J in 
acute asthma. For all DPIs, a higher peak inspiratory flow 
rate will result in more efficient drug delivery, and there 
have been concerns that patients suffering from acute 
asthma exacerbations would not be able to use a DPI in 
the acute asthma situation. However, a study in 99 pa- 
tients with acute asthma exacerbations (mean FEVI = 1.2 I) 
found that the mean flow through Turbuhaler in this 
group of patients was 60 I/min, with all but 2 patients in 
the study achieving flow rates above 30 I/min (8). These 
data are very similar to those obtained in a mild asthmatic 
population (9). A similar study in acute asthma patients 
found that all patients except one (n = 43) could generate 
a peak inhalation flow rate through Turbuhaler greater 
than 30 I/min, and the therapeutic effect (measured by in- 
crease in FEVI after 10 min) was only weakly correlated 
with the inhalation flow rate (10). Hence, both of these 
studies indicate that Turbuhaler is a suitable device for as- 
needed therapy in acute asthma. 
The peak inhalation flows obtained are consistent 
with the clinical results of a study in patients with severe 
acute airway obstruction (mean FEVI =0.91) who, on 
admission to hospital, received 2.5 mg terbutaline viaTur- 
buhaler or pMDI with spacer, followed by a second dose 
after 15 min (11). The improvement in FEVI after 25 min 
was significantly greater (P=0.0004) with Turbuhaler 
than with pMDI plus spacer (Fig. 3). The study by Nana et 
aL (10) also investigated the efficacy of salbutamol, deliv- 
ered via Turbuhaler or pMDI, in 86 patients with acute 
asthma. Salbutamol was given viaTurbuhaler at 0, 15, 30 
and 45 min at doses of 100, 300, 300 and 300#g, respec- 
tively, and the regimen was repeated at 90, 105, 120 and 
135 min, giving a total dose of 2000#g. The same sche- 
dule, with double doses, was used with the salbutamol 
pMDI, giving a total dose of 4000/zg. 
Similar improvements in FEV~ were observed with both 
treatments over the study period of 165 min. Taken to- 
gether, these studies confirm that Turbuhaler can be 
used effectively in patients with acute asthma, providing 
rapid clinical improvement. 
VARIABILITY IN DRUG DELIVERYAND 
THE EFFECT OF PATIENT-RELATED 
FACTORS 
Variability in drug delivery is an important consideration 
for inhalation therapy, and both device- and patient-re- 
lated factors can potentially influence this variability. 
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Figure 3. Increase in FEVI in 62 patients with acute severe 
bronchial obstruction who received terbutaline 2,5 mg viaTur- 
buhaler or pressurized metered dose inhaler (piVlDI) plus spacer 
on admission to hospital, followed by a second dose after 15 rain, 
The improvement in lung function after 25 min was significantly 
greater (P = 0.0004) withTurbuhaler than with pMDI plus spacer 
(I I). [Reproduced with permission from Chest,] 
For DPIs, the respirable fraction obtained will depend, 
to a certain extent, on the inhalation flow rate through 
the device.While it is generally assumed that Turbuhaler 
has a larger flow-dependence than other devices such as 
Diskus ~, a low inhalation flow rate through Turbuhaler 
will result in a similar respirable fraction to that obtained 
with a normal flow through Diskus; consequently, a nor- 
mal flow through Turbuhaler will result in a higher fine 
particle dose to the lungs. 
The flow resistance of a device can also affect the 
variability of drug delivery. Studies have shown that inhal- 
ing against some resistance results in higher and more 
reproducible drug delivery than inhaling against no resis- 
tance (12), although the resistance that results in optimal 
delivery is unknown. 
There have been concerns that devices such asTurbu- 
haler are sensitive to humidity, although a study in 
Australia has demonstrated that Turbuhaler can be used 
effectively in humid conditions (13). Turbuhaler is one of 
the few devices to have a protective cap, and proper use 
of this cap should ensure humidity does not affect the 
performance of the device. 
Studies in healthy volunteers have shown that variabil- 
ity in drug delivery is markedly lower with Turbuhaler 
than with a pMDI (14). Both intra- and intersubject varia- 
bility are reduced withTurbuhaler compared with a pMDI 
(47% vs. 73% and 19% vs. 47%, respectively). Intersubject 
variability is also reduced withTurbuhaler compared with 
pMDI in asthma patients (14).These data indicate that the 
performance of Turbuhaler is less dependent on the indi- 
vidual subject compared with the performance of a 
pMDI, and that Turbuhaler gives a more reproducible 
dose to the lungs than the corresponding pMDI. 
By contrast, variability in vitro has been shown to be 
higher with Turbuhaler (14). This disparity is probably 
due to the fact that in w'tro variability accounts for only a 
small part of the overall in vivo variability in the clinical 
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situation--patient-related factors also impact on the 
variability of inhaler performance (14). 
Patient competence is a problem that is particularly 
pert inent to aerosol therapy, and it has been shown that 
many patients experience problems in using their  inhaler 
correctly (15). This is particularly true of pMDIs, which 
are subject to a number of difficulties. These include the 
need to coordinate inhalation and actuation, and the cold 
freon effect; impaction of the aerosol jet on the back of 
the throat results in a gag reflex and minimal drug de- 
position in the airway. Compliance is a major issue wi th  
all types of therapy; although non-compliance with in- 
haled therapy is known to be common (16), predicting 
which patients are likely to be non-compliant is impossi- 
ble. A third patient-related factor is contrivance; even 
with adequate tuition, patients will often not use their  
inhalers as instructed. 
Of  the patient-related factors that impact on the 
variabil ity of inhaler performance, competence is per- 
haps the most amenable to elimination by improvements 
in the delivery device. The generation of an aerosol and 
its inhalation is a continuous process withTurbuhaler and 
other breath-actuated DPIs, in contrast to pMDIs where 
the two processes are distinct and require coordination 
by the inhaling patient.This functional difference may ex- 
plain why lung deposition is more predictable when using 
Turbuhaler compared with a pMDI (14). 
CONCLUSIONS 
The clinical effect of an asthma drug relies on its pulmon- 
ary deposition, which in turn is dependent on the fine 
particle dose of the generated aerosol. In vitro data show 
a better correlation with in vivo data if an anatomically 
accurate replica human throat is used as an inlet to the 
impactor. 
Effective management of asthmatic patients relies on 
achieving adequate delivery of inhaled drugs to the lungs. 
Several factors can influence pulmonary deposition, in- 
cluding the performance of the delivery device itself and 
patient handling. Turbuhaler has been shown to deliver a 
more reproducible dose than a pMDI, suggesting that the 
performance of Turbuhaler is less dependent on the pa- 
t ient compared with a pMDI. In addition to providing a 
more reproducible dose than a pMDI, Turbuhaler has 
been shown to provide superior lung deposition, leading 
to a superior clinical effect. Especially, Turbuhaler has 
been shown to deliver more drug to the lungs compared 
with  Aerolizer. Concerns regarding the use of DPIs such 
as Turbuhaler in acute asthma would appear to be un- 
founded, with several studies demonstrating thatTurbu- 
haler provides rapid clinical improvement when used for 
as-needed therapy in acute exacerbations.Thus,Turbuha- 
ler provides several improvements over alternative deliv- 
ery devices for the effective management of asthma. 
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